Campbell & CO Investment Adviser LLC Invests $1.30 Million in Arcus Biosciences, Inc. $RCUS

Key Points

• Campbell & CO Investment Adviser LLC made a new investment of approximately $1.30 million in Arcus Biosciences, acquiring 165,474 shares, which represents about 0.16% of the company.
• Arcus Biosciences reported its earnings with a 310.3% year-over-year revenue increase, having generated $160 million, significantly surpassing analysts' expectations of $32.86 million.
• Brokerages have recently adjusted their ratings and price targets for Arcus Biosciences stock, with six analysts rating it as a Buy and a consensus price target of $21.14.

Campbell & CO Investment Adviser LLC purchased a new stake in shares of Arcus Biosciences, Inc. (NYSE:RCUS - Free Report) in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 165,474 shares of the company's stock, valued at approximately $1,299,000. Campbell & CO Investment Adviser LLC owned 0.16% of Arcus Biosciences as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Allspring Global Investments Holdings LLC grew its stake in shares of Arcus Biosciences by 54.0% during the 1st quarter. Allspring Global Investments Holdings LLC now owns 18,405 shares of the company's stock valued at $144,000 after purchasing an additional 6,453 shares during the period. Yousif Capital Management LLC grew its stake in shares of Arcus Biosciences by 18.6% during the 1st quarter. Yousif Capital Management LLC now owns 24,829 shares of the company's stock valued at $195,000 after purchasing an additional 3,893 shares during the period. Amalgamated Bank grew its stake in shares of Arcus Biosciences by 18.4% during the 1st quarter. Amalgamated Bank now owns 18,797 shares of the company's stock valued at $148,000 after purchasing an additional 2,922 shares during the period. Raymond James Financial Inc. bought a new stake in shares of Arcus Biosciences during the 4th quarter valued at about $531,000. Finally, Rhumbline Advisers grew its stake in shares of Arcus Biosciences by 14.8% during the 1st quarter. Rhumbline Advisers now owns 182,909 shares of the company's stock valued at $1,436,000 after purchasing an additional 23,645 shares during the period. 92.89% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of research analysts recently issued reports on the company. Wedbush reiterated an "outperform" rating and set a $33.00 price objective on shares of Arcus Biosciences in a research note on Wednesday, May 7th. Wells Fargo & Company cut their price objective on Arcus Biosciences from $26.00 to $25.00 and set an "overweight" rating for the company in a research note on Thursday, August 7th. Morgan Stanley cut their price objective on Arcus Biosciences from $24.00 to $22.00 and set an "overweight" rating for the company in a research note on Friday, May 9th. Wall Street Zen upgraded Arcus Biosciences from a "strong sell" rating to a "hold" rating in a research note on Saturday, August 9th. Finally, The Goldman Sachs Group cut their price objective on Arcus Biosciences from $15.00 to $13.00 and set a "neutral" rating for the company in a research note on Thursday, May 8th. Six research analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus target price of $21.14.

Arcus Biosciences Price Performance

NYSE RCUS traded down $0.02 during trading hours on Friday, reaching $10.60. The company's stock had a trading volume of 548,275 shares, compared to its average volume of 759,613. The firm's 50-day moving average price is $9.42 and its 200-day moving average price is $9.17. The company has a quick ratio of 4.50, a current ratio of 4.50 and a debt-to-equity ratio of 0.18. Arcus Biosciences, Inc. has a 1 year low of $6.50 and a 1 year high of $18.98. The company has a market capitalization of $1.13 billion, a price-to-earnings ratio of -3.34 and a beta of 0.89.

Arcus Biosciences (NYSE:RCUS - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($1.11) EPS for the quarter, topping analysts' consensus estimates of ($1.14) by $0.03. Arcus Biosciences had a negative return on equity of 55.96% and a negative net margin of 109.56%.The company had revenue of $160.00 million for the quarter, compared to analysts' expectations of $32.86 million. During the same period in the previous year, the firm earned ($1.02) EPS. The firm's revenue was up 310.3% compared to the same quarter last year. On average, equities research analysts predict that Arcus Biosciences, Inc. will post -3.15 EPS for the current fiscal year.

Arcus Biosciences Profile

Arcus Biosciences, Inc, a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies.